Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is only the beginning, Lets just take one step at a time and our next step is to officially make it past the 10 days above $1
Next... we wait for the new analyst coverages ... and current analyst upgrades .... all which should have been states within 2 days after that last conference call. I mean an analyst is supposed to analyze the facts at hand and not be responding by how the stock trades, even we knew after that conference call that it was a matter of time before we're pushed to higher ground.
Next ... it would be nice to hear the PR that Peregrine has been approved for the bridge loan using Avids as collateral since they have 30 Million in orders for the next 2 years ... b u t .... they may not need the loan at all with a BP Partner deal that can be closed.
Next... going concern should be off the table by next quarter
Next... show some confidence Peregrine and take some of your cash... take a portion of your bridge loan ... and announce a stock buyback! It doesn't have to be in the 10 million shares... a simple vote of confidence right now saying you plan on buying 1 Million shares back goes a long way with the shareholders and Big Pharma a like. This buyback helps keep the stock rising and directly results the bargaining that Big Pharma will eventually being paying for us ( think of it as doing your kitchen or bathroom over before selling the house.... a little investment ( buyback ) now... will be rewarded when all is said and done.
Next... well lets leave it like that for the time being... should put us in trading range of $ 3-7 before more trial data is released.
Good luck to all... and remember, don't get caught with your shorts down : )
I agree... absolutely, the only way for Big Pharma to really get their payday is to give Peregrine their payday! Then... they can start many trials to asap because the quicker the 1st rounds and 2nd rounds of data get in... the bigger the payday is for big-pharma.
The more I think about it... there is no way a deal will be made for one use of Bavi ( lung cancer ) ... the 1st Big Pharma to jump on board will have the 1st right of refusal for all other uses but this means Peregrine's payday will be here and future royalties depending on how the deal is structured. My main point is the upfront payment will be larger than most can imagine.
Hi Jake... I can relax a little with the guessing how high we can go but I do think we deserve this after years of patiently waiting. I have some friends that ... after doing their own due diligence .... can't believe the facts at this point are glad I told them to check it out and the risk/reward is absolutely worth it.
You said you have been invested in this stock for 17 years? I only wish I could have your patience and hopefully its about to pay off dearly for us all.
The next time you drink your Dunkin Donuts coffee, take a look at the "Dart" lid on that plastic lid and you're in the company of a 5% shareholder in PPHM : ) I would guess that we will have one more 5% shareholder by the next quarter along with Dart and BlackRock
I would like to see Bill Gates Foundation or Warren take the plunge here... do you think one of the richest guys in the world would want to be left out of a possible big cancer play over the upcoming years, I hope not..
Avid will thrive once this ... well hopefully once a partnering deal can be completed because any large BP would surely benefit from having Avid as well and this is just another reason why the "possibility" is there.... and we can't deny that it is a possibility because I don't know of any other small biotech with the depth of potential value that Peregrine holds.
I do remember an article that came out last year that stated Peregrine was one of the top small biotechs that were unpartnered... to be specific, PPHM was listed as #8 on the list (this was as of August 2010 ) of the top unpartnered bio's so I would say at this stage... we're on the very top!
http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=220755
There are many major BP's out there that have cash and patents expiring for their major drugs and this is one major purchase that can get them back into the game for years : )
ok... I can hope : ) but its no longer the pipe dream that many would say 2+ years ago
How about buying back 1 Million in shares... now that would show some confidence for sure!
... I know we are not aware of the money issues.... but if they do have 18M cash on hand... even a simple press release saying they plan on buying back 1 Million shares every quarter and that would send a strong message that the dilution days are over
just thinking out of the box... but I'm sure they have other concerns to worry about... like a multi-billion dollar partnering deal : )
geocappy1..
This should all work in Peregrines favor and the point about our Phase II being held to the "Gold Standard" which is typically reserved for Phase III...... is this gold standard mainly designing a trial around "using MOS to determine success/failure as in our Phase IIb" May 21st results .... Verse ..... as the article mentions designing a trial around "tumor shrinkage".. that does not translate into extending life.
I would like to see some type of comparison... or even someone ask Garnick next time... or sometime... how many trials are designed at the gold standard .... or are these gold standard trial designs only reserved for a data that is the most compelling data : ) as Garnick quoted on the last conference call!
It will certainly be a good year for Peregrine if all continues as planned
Steven King video: talking Ph II trials -- back in 2009
geocappy1...
I was thinking the exact same thing! ... and was looking thru some google searches and unable to find anything. Here is one article I came across re: partnered vs. unpartnered
Attrition High for Biotechs Without Partners; Worth It?
96% of unpartnered cancer drugs fail -
http://dialog.newsedge.com/portal.asp?site=2007100814443105593225&searchfolderid=pg2007100814522209759333&block=default&portlet=ep&nzesm=on&syntax=advanced&display=New+Drugs&action=sitetopics&mode=realtime&nzenb=left&criteria=[topic%3Dnewdrugs]&searchID=730071&datetime=[t-minus%3D7]&hdlaction=story&storyid=[storyid=vVLjEmU78eywb8J5V0IdMMajvPueo8tX-06h_Fe9SF6YAZrn33SQDQ9aXo2WnPxuG8Da7dI0aLQrYjZBxnflgA**]&rtcrdata=on&epname=USDOLLAR&
----------------
The article does mention needing the regulatory experience is the one top reason that a partner is needed... though Garnick surely provides us with that experience. I do believe we will partner up eventually and again, I think Garnick warrants Peregrines respect from many of the top BP's
Insiders can't buy right now? I missed that in the conference call or report ... did they mention that on the call or in the report?
thanks in advance!
1.285 ... I thought the 1/100th's place.. 3rd decimal days were over... we will dedicate this .005 to Adam : )
1.29..! do I hear 1.30... I think we all have to band together next week because Adam and company may be coming back with another plan that will hopefully fall short : )
1.28 and we can all sleep peacefully over the weekend : )
another new HOD 1.26 ... this trading week has been fun to watch and trading patterns that have never existed with Peregrine before! : ) Hoping to see 1.28 by the end
Looking forward to next week
dJohn.... thanks for the link... I'll add one to... maybe we can keep a tally sheet on any and all sites associated with Adam Feuerstein...
------------------------------------
as dJohn posted before...
GNBT and now PPHM is management watching?
Generex Biotechnology Corporation (GNBT) Launches $250,000,000 Lawsuit Against TheStreet.com and Feuerstein; Company Seeks Damages
----------------------------------
Feel free to add some sites when we come across them.... in the meantime I will be looking back at all his stories from the beginning and checking the history of the stock prices of the companies thereafter.... TheStreet.com should make it public how many complaints there are against this Adam Feurerstein and we will find out
1) This site is dedicated solely to Adam Feuerstein and provides overwhelming facts that when he writes... he is not neutral and working to drive stock prices down
http://www.exposeadam.com/
2) This site makes everyone aware that his writings actually brought a 250 Million lawsuit against him on April 6, 2010 it was reported
http://www.fiercebiotech.com/press-releases/generex-biotechnology-corporation-gnbt-launches-250-000-000-lawsuit-against-thestreet
Looks like the author Adam Feuerstein has a lot more troubles in his past with being sued and many other ethical issues about writing one sided wall street stories
I hope anyone who is going to read any of his articles regarding Peregrine will see the true Adam Feuerstein below:
Adam Feuerstein
http://www.exposeadam.com/
I completely agree .... and have orders already in place to lock up the shares
This is what happens when the short start losing money or the price is being held down for others to join in
As for the talks about PPHM exec's or management being sneaky? ... they are baseless and atleast all of the longs on board have the data trial facts to back us up ... we will fight thru this negativity for sure : )
Peregrine is a diamond in the rough!
Someone (or something) that has hidden exceptional characteristics and/or future potential, but currently lacks the final touches that would make them (or it) truly stand out from the crowd.
You can look for years and a lifetime to try and find a pharma stock with this potential at this stage in the game trading at 1.25 ... and we will hopefully : ) be all looking back a year from now and begin to appreciate what we all have stumbled upon. Some tied up for years and some just joining and those just joining I am jealous! : ) You did not have to go thru the quarterly conference calls and reverse splits and stock dilution and stress lol If I had to do it over again, I wouldn't change a thing though... I think you appreciate it that much more in the long run
I can agree with that...but maybe just maybe....PPHM holds some leverage due to strong results and the expiring patents of many major drugs... and just maybe some... all we need is one ....one BP to take the plunge and offer a major upfront payment with yearly installment payments up to 10 years or so assuming all milestones are met.
This way... we get under some BP protection... monies....and allow some major trials to move full steam ahead.
Lets play along... if BAVI is the true answer and a broad platform drug.... I am sure some type of longterm agreement can be reached....we are not getting younger and everyone wins....
Ok....maybe I am being impatient here but I am an optimistic and good things are to come our way....
The chart shows some leveling off.... what is in store for us on a friday? Lets keep her wound up nice and tight and get ready for that next move up which may require some news to get this party started again!
Weak hands out at low of 1.21 ... now what will the new high be today?
I'll say 1.52
PG... I agree, PPHM sits at 1.35 and I have never seen a stock atleast that I had this much confidence in or I would have bought in, but these stocks come once in a lifetime and for those who have been here from the beginning and can finish painting the picture 3-6 months from now and what could be... could be... its not a pipe dream no longer.
I have bought stock before and lost money listening to all the hype but there is way too much detail in this stock and its all coming down to the need for all details to be scrutinized and Garnick and company are the right ones with the experience from Genentech to complete the job.
I know I have high expectations but I'd be more than happy to settle for a 3-20% gains weekly for the rest of the year.
One note.... my thoughts of 40-75 sell right now....is not my # when more data comes or post phase III.... by then we will be in $100 range plus plus
The one worry I have is that if for some reason they take a buyout for the entire platform.... its will be a figure that surely surpasses my sell order. Fidelity is currently not allowing sell orders above $15.... and atleast in my opinion we will be fetching between $40-75 so here I will hold my ground and have no intentions of willing to sell at $15
They say everyone has a $ number to be happy and walk away.... $15 is far from it and by the confidence level and extremely small details that were announced last cc....PPHM's # is far fron $15 as well! Lets sit back and enjoy the ride : )
Does placing an order to sell your shares protect them from naken shorting... I have heard this in the past many times and hopefully we don't have to worry about that here since we've reached the inflection point... but does anyone have any thoughts on placing an order to sell your shares?
I did miss that post! : ) .....well good luck today...and hope to see a new analyst jump the bandwagon
St. Peregrine: the patron Saint of cancer patients..
I just found this out... possibly the reasoning behind the use of the original name of the company.
http://www.saintgeo.com/peregrine.htm
I agree.... and todays continuation of high volume and closing near the top shows the strength of this stock that has not been shown before. Well maybe back in 2000 for the pop to 16 but those were the bubble days and we are clearly showing strength as we move away from the little engine stock and becoming the little engine that could : )
One additional area that helps us is the patent expiration of many of the large BP's .... as shown here...
http://www.ft.com/cms/s/0/572ea510-9452-11e1-bb47-00144feab49a.html#axzz212QAW96c
15 Meetings with BP's... and attorney on the payroll... get ready folks : )
Where it all began: for those just beginning to research this company... the below article mentions "vascular targeting agents" .. and their lead targeting agent is now known as the soon to be widely known "Bavituximab" .. or Bavi
1997 - 2012 ... a long 15 years in the making...
Techniclone bought Peregrine and changed our name to Peregrine.
(BW)(TECHNICLONE/PEREGRINE)(TCLN) Techniclone announces agreement to acquire
Peregrine Pharmaceuticals
Business Editors
TUSTIN, Calif. -- (BUSINESS WIRE) -- Jan. 16, 1997 -- Techniclone
Corporation (NASDAQ:TCLN), a biotechnology company engaged in the research,
development and commercialization of therapeutics to treat cancer announced
today that it has entered into an agreement with several major stockholders of
Peregrine Pharmaceuticals, Inc. to acquire a majority of the shares of
Peregrine.
Upon completion of the stock for stock exchange, Techniclone will own a
controlling interest in Peregrine. Peregrine, a privately-held company based
in Princeton, New Jersey, is a biotechnology firm developing a new type of
cancer treatment known as Vascular Targeting Agents (VTAs), which are a second
generation of therapies to emerge from research in tumor angiogenesis. Tumor
angiogenesis is the formation of blood vessels and capillaries, which is
necessary for tumor growth.
Peregrine has 1,125,390 shares of stock outstanding. If all of
Peregrine's Stockholders elect to enter into the agreement with Techniclone to
exchange their shares for shares of Techniclone common stock, Techniclone will
issue approximately 4,725,000 shares to acquire all of Peregrine's stock. The
actual number of shares to be issued by Techniclone is subject to adjustment
based on the amount of Peregrine liabilities assumed by Techniclone at the
closing date.
Peregrine scientists have been developing agents which selectively
clot, or coagulate, the solid tumor vessels and capillaries, blocking the flow
of oxygen and nutrients to underlying tumor tissue, which then starves the
tumor. In preclinical studies, clotting occurred within hours of treatment,
creating an avalanche of cell death in the underlying tumor tissue, leaving
nearby healthy tissue intact and fully functional. Similar to Techniclone's
patented Tumor Necrosis Therapy (TNT) technology, Peregrine's VTAs are
believed to be universally effective against most solid tumor cancers through
the administration of a single agent, with little or no toxicity. Key
scientific research for Peregrine takes place at the University of Texas
Southwestern Medical Center, under the leadership of Philip Thorpe, Ph.D., who
is a co-founder of Peregrine and the inventor of VTA.
"The potential synergy the Peregrine acquisition creates is exciting.
We look forward to working with their scientific team, led by Dr. Thorpe, to
further improve and expand Techniclone's product pipeline," said Techniclone
Director of Scientific Affairs, Alan L. Epstein, M.D., Ph.D. "VTAs create
large amounts of necrosis (cell death) in solid tumors, and TNT works by
targeting those necrotic (dead) areas. Increasing the amount of necrotic tissue
within the tumor is expected to increase the efficacy of Tumor Necrosis
Therapy. Although TNT and VTA technologies are designed to be used
independently of each other, a powerful "one-two punch" could be created by
pre-treating with VTAs and subsequently treating with TNT. We believe this
combination could bring about an entirely new approach to solid tumor cancer
treatment, with Techniclone at the forefront."
"We are enthusiastic about the potential that the acquisition of
Peregrine offers," said Techniclone CEO Lon H. Stone. "Peregrine has acquired
rights to all of the known patents and patent applications covering the
vascular targeting field, and is also a licensee of several other key patents
and patent applications covering specific components and targeting mechanisms
used by its VTA drug compounds.
EX-99 Last Page of 2 TOC 1st Previous Next Bottom Just 2nd
Peregrine's VTAs are not yet in clinical trials and are at least 18 months
behind the expected clinical testing of TNT. The acquisition helps ensure a
continuous flow of new and complementary products to the market into the
foreseeable future. Because of common production methods and disease focus, the
continued preclinical development of VTAs should not have a significant impact
on Techniclone's near-term capital expenditure program."
Closing of the transaction is currently scheduled to take place in
early 1997. Peregrine's co-founder and CEO, Jennifer H. Lobo, will serve as a
consultant to Techniclone, focusing on business financing, technology licensing
and corporate joint ventures. Ms. Lobo has extensive background as a venture
capitalist and biotechnology strategist, having been previously a founder of
Domain Associates and a partner with Rothschild Ventures, Inc.
----------------------
ok... here are my figures:
1) $2 -- 100%
2) $5 -- 100%
3) $10 -- 100%
4) $20 -- 100%
By Oct 18, 2012 .... we will be at $20 ... simple as that
The MM's I believe are letting this run because they no longer have any real control over the movement of this stock... the value is being revealed and thank goodness for a conference call that actually displayed some confidence and explanation down to many details that were never mentioned in the past! The mention of the many little details clearly conveys that we have a winner ( well in my honest opinion ! : )
What next?
1) Analyst upgrades for one... lets hear our first analyst pick up of this stock tomorrow morning.. I hope! and can't wait to hear our first 12-month price target
June 29, 2011 ... Garnick talks Bavi... this was one of my favorite write ups at the time and at this time the stock was just under $2 so I hope we get back to $2 very soon : ) and continue to trend line upward
http://www.minyanville.com/businessmarkets/articles/peregrine-pharmaceuticals-bavituximab-robert-garnick-steven/6/29/2011/id/35458
You left out one more downside... they will need to spend some more money on another Merger/Acquisition attorney: there is no way one single attorney they have now can keep up with all the phone calls and meetings they have scheduled : )
I think its comical that we all sit here knowing more than many of the analysts that are still trying to digest all the data from Peregrine Pharmaceuticals ... as no new analysts have jumped ahead of the curve on this one yet! : ) Will they initiate a couple newbies with a buy rating after we hit $5 ? Lets go analaysts, you afraid to predict the unthinkable? that a stock such as Peregrine could make it this far .. or you worried about the bridges you going to burn with the competitors ?
Similar to the fastest bird-Peregrine falcon in the sky that can reach speeds of 200 mph ... Peregrine will hopefully fly as fast and could even reach $200
it would just be nice to see how large the group will get....also you could make it an open or closed group.....open group means anyone sees the postings....vs closed group only the ones in the group sees the postings.... id be ok with open group and i do understand wih some being anonymous but its not like you need to have pphm stock to be part of the group.... many will join simply because a cure for cancers is good to be part of...
You are not dreaming... in time we will be rewarded well
How many here were around for the techniclone days before they changed their name Peregrine? ..... someone should create a PPHM investment page before we really start to take off.... even possibly try and transfer all the "intro" data on a site like facebook where this will get noticed more easily....any other ideas?
Good estimate of 5.4 Billion .... another major factor that will entice all BP's to get their pipelines in order is the amount of 65+ aged population increasing dramatically over the next 15 years
http://www.aoa.gov/AoARoot/Aging_Statistics/Census_Population/census2010/Index.aspx
We are clearly going to be well above any estimates currently... so 5-6 Billion is a very safe figure to use
Going to be a good year till we finally get some tally for what % this platform or more of this company will be valued at.... I'm aiming high : )
IF we are in talks with up to 15 BP's... which the number was never really given. Was it 15 meetings with 15 different BP's ? I know they said on the cc multiple BP's so its safe to say we have atleast 3 BP's in talks with PPHM and I would say probably more than 3.
Now... I'm sure each is playing their cards right and purchasing plenty of shares in case they end up on the short end of this partnership..etc and they can profit on the way up to whomever partners. I think back to the days of techniclone when it ran from 2 or 3 to $15-16 and although times are different we have a much improved pipeline and depth to this company at this point compared to back then and I see no reason why we shouldn't be sitting at $10 by months end.
thats an easy 3x bagger from this time.... and lets get this party started and enough of the lows we've seen before with 2/10 th's of the trial data and overall positive news back then!
No way we will be sitting at these levels for much longer... just all in my honest opinion : ) My prediction for tomorrow: a new analyst to begin coverage and/or updated coverage from current ones
Brings chills and excitement every time you read that part of the conference call! : )
Question regarding the partnering meetings. First of all, thanks for letting us know that you've had several, I think 15 you said. Are you willing to characterize whether or not these are with large pharmaceutical partners and if you prefer a U.S.-only deal or a worldwide deal or a non-U.S. deal? And then finally, are they with partners who are mostly oriented to chemotherapies, say, in lung cancer? Or partners who are actively pursuing or have pursued in the past immunotherapy in lung cancer?
Steven W. King
Sure, yes. I think that I would characterize most of the meetings we've had with -- have been with large pharmaceutical-type companies that are active in the oncology space. Of course, many if not all of these companies would have had chemotherapy-type agents in development. And ideally, we want a partner with some biologics experience. And so I think a, again, a majority of the potential partners have some sort of biologics experience in the space as well.
shorties are wondering what the heck to do at this point... do they want to wake up one morning to find we've jumped up 2-3-4 or 500% and be squeezed out ... or do they join the party!
There will not be much selling here ... this puppy has been fenced in for 15 years and may have been allowed to run for a couple days in the past but she is free to run with hopefully no one holding her back!
All the reasons I look back into the past still hold true for why I thought this stock could have this potential.
1) The broad potential of the drug itself to extend life.
2) The recruitment of Garnick/Shan..etc...etc.. some from Genentech...some from Abbott... this was crucial to see they were jumping on board! ... and all have been in these circles before and working similar drugs to market, especially Avastin where our trials were proven to be better!
3) The multiple sets of stock options they would have the chance to purchase at low levels giving them the incentive to jump and stay on board!
4) The Poison Pill
5) The Avid deal... ! How many other young bio-pharms have this type of in house set up??
6) The Imaging technology now ! Its like the perfect stock and one where other start ups will try and imitate the success of PPHM. Yes! I do agree when all is said and done... there will be case studies in business schools studying the progress and decisions PPHM has made.
7) Too much more to list.. the latest may be the hiring of a M/A attorney... what I would like to see / work on .. is a complete list of top employees they recruited from other BP's
I see we have hit 1.20 now.. keep it going!